← Leaderboards
Josep Bassaganya-Riera
Virginia Polytechnic Inst And St Univ
$16,010,213
Attributed
$16,010,213
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $10.9M · FY2007–25$20M$15M$10M$5M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,010,213 · 11
By mechanism
N01$12,071,877 · 1
R43$2,259,588 · 7
R01$1,190,839 · 1
R44$299,576 · 1
R41$188,333 · 1
Top collaborators
No co-investigators on record.
Most similar at Virginia Polytechnic Inst And St Univ
Same institution · by research overlap
- Thomas J. Inzana$375,604
- Yasuhiro Suzuki$11,960,130
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsInflammationInflammatoryResponseImmuneReceptorLungImmunoregulationCytokineOralBiological Response Modifier TherapyCommercial ApplicationSafetyTreatment EfficacyBasePharmaceutical PreparationsBiotechnologyMouse ModelImmune ResponseDoseMacrophageChemokineChronicLigands
Grant awards (15)
Next-Gen Oral Therapeutics for Type 2 Diabetes$359,625
R43 · FY2025 · DK · contact PI
The Next Wave of Asthma Therapeutics$347,608
R43 · FY2025 · HL · contact PI
Development of Novel Immunoregulatory Therapeutics for Asthma$355,935
R43 · FY2024 · HL · contact PI
Development of Novel Therapeutics for Asthma$288,986
R43 · FY2024 · HL · contact PI
Novel first-in-class Therapeutics for Rheumatoid Arthritis$295,924
R43 · FY2023 · AR · contact PI
Targeting the Immunometabolic Hub Nlrx1 as a Novel Therapeutic for Asthma$361,510
R43 · FY2021 · HL · contact PI
BT-11: A First-in-class Oral Therapeutic for Inflammatory Bowel Disease$299,576
R44 · FY2018 · AI · contact PI
The First Abscisic Acid-Containing Medical Food for Glycemic Control$250,000
R43 · FY2016 · DK · contact PI
Modeliing immunity for Biodefense:Enteroagressive E. coli and Helicobacter pylori$1,500,000
N01 · FY2015 · AI · contact PI
Development of Novel LANCL2-based Anti-diabetic Compounds$188,333
R41 · FY2013 · DK · contact PI
Modeliing immunity for Biodefense:Enteroagressive E. coli and Helicobacter pylori$10,571,877
N01 · FY2010 · AI · contact PI
Mechanisms of Immune Modulation by Abscisic Acid$289,099
R01 · FY2010 · AT · contact PI
Mechanisms of Immune Modulation by Abscisic Acid$323,398
R01 · FY2009 · AT · contact PI
Mechanisms of Immune Modulation by Abscisic Acid$287,319
R01 · FY2008 · AT · contact PI
Mechanisms of Immune Modulation by Abscisic Acid$291,023
R01 · FY2007 · AT · contact PI